07:35 AM EDT, 05/23/2025 (MT Newswires) -- Invivyd ( IVVD ) said Friday its investigational monoclonal antibody Pemgarda has been added to the National Comprehensive Cancer Network's clinical practice guidelines in oncology for B-cell lymphomas.

The product's inclusion in the cancer non-profit's guidelines recognizes it as a potential option for pre-exposure prophylaxis against COVID-19 in patients with B-cell malignancies, the company said.

The company's shares were up 10% in recent premarket activity on Friday.